检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:徐志豪[1] 刘富光[1] 王选锭[1] 卞如濂[1] 哈培蓉[2] 严浩 李荣生 沈根宝
机构地区:[1]浙江大学医学院附属第二医院,杭州310009 [2]成都市第二人民医院,成都610041 [3]解放军成都军区总医院,成都610083 [4]成都药业有限公司,成都610021
出 处:《中国临床药理学杂志》2000年第2期83-86,共4页The Chinese Journal of Clinical Pharmacology
摘 要:本研究以茶碱缓释片为对照,采用随机双盲双模拟多中心临床试验设计,评价复方茶酮缓释片治疗支气管哮喘的有效性和安全性。随机对照试验的药品按双盲双模拟要求制备,两组病人均服用3片试验药,复方茶碱缓释片每片含茶碱 200mg,酮替芬1mg;对照药茶碱缓释片每片含茶碱 100mg(双百双模拟片一大二小),q12h,轻度病人1周,中度病人6周。试验组103例,对照组100例,分别有50例和41例观察单剂量顿服的即刻平喘疗效。试验组和对照组1周临床有效率分别为 90.9%和 75.7%,肺功能改善率分别为 87.9%和 72.4%; 6周临床有效率分别为82.9%和74.6%,肺功能改善率分别为90.8%和82.1%。即刻平喘试验表明两组均具有缓慢释放的特点。两组药物不良反应发生率分别为7.7%和9.0%。结论为复方茶酮缓释片是一有效而且安全的平喘药物。This study was designed as double-blind double-dummy randomized controlled multicenter clinical trial to evaluate the efficacy and safety of theophyiline-kelotifen sustained-releasing compound tablets in the treatment of asthma compared with theophylline sustained-releasing tablets. In the randomized groups, the study drugs were enveloped in double-blind double-dummy manner. The subjects with mild asthma took 3 pills (1 big pill and 2 small pills),q 12h for I week and those with moderate asthma for 6 weeks. The efficacy was investigated on nearly half of the subjects in each group after one-dose administration. The clinical efficacy of the tested group after 1-week duration was similar to that of the control group, and so as the results of lung function efficacy. After 6-week treatment, the clinical efficacy rate was 82.9% which was better than that of the control group; and the lung function efficacy rates were 90.8% and 82. 1 % respectively in the two groups. The investigation on one-dose administration suggested the study drugs had the characteristics of sustained releasing. The rate of adverse drug reactions of theophylline-ketotifen compound tablets was 7.7%.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.28